Antiangiogenic therapy for cancer: an update

Cancer J. Nov-Dec 2007;13(6):345-8. doi: 10.1097/PPO.0b013e31815a7b69.

Abstract

The identification and characterization of several important regulators of angiogenesis, which led to Food and Drug Administration approval of the first antiangiogenic drugs, has opened a new era in cancer therapy. This article focuses on the clinical progress in targeting one of the major regulators of angiogenesis, vascular endothelial growth factor-A and also discusses some recent advances in the elucidation of potential cellular and molecular mechanisms underlying refractoriness or resistance to antiangiogenic therapies.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Drug Approval
  • Humans
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neovascularization, Pathologic / prevention & control
  • United States
  • United States Food and Drug Administration
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / genetics

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A